Skip Navigation


European Heart Journal Advance Access originally published online on July 11, 2006
European Heart Journal 2006 27(18):2145-2146; doi:10.1093/eurheartj/ehl151
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/18/2145    most recent
ehl151v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Emdin, M.
Right arrow Articles by Paolicchi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Emdin, M.
Right arrow Articles by Paolicchi, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Gamma-glutamyltransferase as a cardiovascular risk factor

Michele Emdin1,*, Claudio Passino1,2, Alfonso Pompella3 and Aldo Paolicchi3

1 Cardiovascular Medicine Department, Institute of Clinical Physiology, National Research Council (CNR), Via Giuseppe Moruzzi 1, 56124 Pisa, Italy
2 Scuola Superiore Sant'Anna, Pisa, Italy
3 Department of Experimental Pathology, University of Pisa Medical School, Pisa, Italy

* Corresponding author. Tel: +39 050 3152189; fax: +39 050 3152109. E-mail address: emdin@ifc.cnr.it

This editorial refers to ‘Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28 838 middle-aged men and women’{dagger} by D.-H. Lee et al., on page 2170

The first 10% of the full text of this article appears below.

The association of a novel factor with clinical vascular disease must meet the same high standard met by ‘traditional’ risk factors. Serum gamma-glutamyltransferase (GGT) activity is a low-cost, highly sensitive laboratory test: though it is currently considered as an index of hepato-biliary dysfunction and alcohol abuse,1 pathology studies from our group since 1998 have indicated its possible role in the pathogenesis of atherosclerosis.2,3 Furthermore, epidemiology studies on a total of 218 561 subjects from unselected populations4–6 or cohorts with ascertained disease7 have proven the role of GGT not only in predicting mortality from all causes, but also the clinical . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28 838 middle-aged men and women
Duk-Hee Lee, Karri Silventoinen, Gang Hu, David R. Jacobs, Jr, Pekka Jousilahti, Jouko Sundvall, and Jaakko Tuomilehto
EHJ 2006 27: 2170-2176. [Abstract] [FREE Full Text]